FDA OKs Overdose Treatment Device

The U.S. Food and Drug Administration approves a long-awaited handheld device for the treatment of opioid-overdose emergencies.

Written byRina Shaikh-Lesko
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

CENTERS FOR DISEASE CONTROLThe U.S. Food and Drug Administration approved a handheld device from the Richmond, Virginia-based firm Kaléo Pharma to treat opioid overdoses this week (April 3). Called Evzio, the auto-injector—a rectangular device smaller than a deck of cards that delivers a single dose of the drug naloxone—is meant to be used by the suspected overdose victim’s family or caretakers and requires a prescription. FDA fast-tracked Evzio and approved it in just four months from its submission—quickly enough that its manufacturer has not yet set a price.

The U.S. is in the midst of a prescription painkiller epidemic. In 2009, more than 16,000 people died from opioid overdoses in the country. And ongoing efforts to develop a non-addictive pain killer have yet to bear fruit.

The new device works to treat opioid overdoses much in the same way EpiPens are used to treat anaphylactic shock from severe allergic reactions. When opened and activated, the device emits recorded voice instructions to guide users. Regulators warned, however, that the device offers only temporary treatment, and is not meant as a substitute for emergency medical treatment. (The device’s instructions include calling 911.)

“For years, the lack of a lay-friendly delivery system has made it difficult to make naloxone broadly available to the public and to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies